APA (7th ed.) Citation

Kuboki, Y., Pietrantonio, F., Salvatore, L., Esaki, T., Modest, D., Paez, D., . . . Fakih, M. (2023). 91MO Sotorasib plus panitumumab versus standard-of-care for chemorefractory KRAS G12C-mutated metastatic colorectal cancer (mCRC): CodeBreak 300 phase III study. Annals of Oncology, 34, S1504. https://doi.org/10.1016/j.annonc.2023.10.226

Chicago Style (17th ed.) Citation

Kuboki, Y., et al. "91MO Sotorasib Plus Panitumumab Versus Standard-of-care for Chemorefractory KRAS G12C-mutated Metastatic Colorectal Cancer (mCRC): CodeBreak 300 Phase III Study." Annals of Oncology 34 (2023): S1504. https://doi.org/10.1016/j.annonc.2023.10.226.

MLA (9th ed.) Citation

Kuboki, Y., et al. "91MO Sotorasib Plus Panitumumab Versus Standard-of-care for Chemorefractory KRAS G12C-mutated Metastatic Colorectal Cancer (mCRC): CodeBreak 300 Phase III Study." Annals of Oncology, vol. 34, 2023, p. S1504, https://doi.org/10.1016/j.annonc.2023.10.226.